Drug: |
||||
---|---|---|---|---|
Trial Name: |
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
2 |
Start Date 01/01/2009 |
Age of Trial (yrs) 15.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor + DR5 Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
20070411 |
|||
Sponsor: |
Amgen |
|||
Patient Contact: |
Amgen Call Center
866-572-6436 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Excludes patients who have received prior IGF-1R inhibitor therapy. Marked as "no GIST allowed' pending confirmation from Jennifer Ott at University of Chicago. Trial is about to enter phase 2. Verified that trial will accept GIST with Hedy Kindler. |
Trial Links |
Trial Results |
Drug Information |
Name |
Address |
City |
State |
Zip |
Country |
2811 Wilshire Blvd |
Santa Monica |
CA |
90403 |
USA |
|
Indianapolis |
IN |
USA |
|||
Detroit |
MI |
USA |
|||
Barcelona |
08036 |
Spain |
|||
1500 E. Duarte Road |
Duarte |
CA |
91010 |
USA |
|
Palo Alto |
CA |
94304 |
USA |
||
660 S. Euclid Ave |
St. Louis |
MO |
63110 |
USA |
|
2220 Pierce Ave. |
Nashville |
TN |
37232 |
USA |
|
Los Angeles |
CA |
USA |
|||
Chicago |
IL |
USA |
|||
Harvey |
IL |
USA |
|||
Baltimore |
MD |
USA |
|||
Boston |
MA |
02115 |
USA |
||
Chapel Hill |
NC |
USA |
|||
Durham |
NC |
USA |
|||
Philadelphia |
PA |
USA |
|||
Ogden |
UT |
USA |
|||
Valencia |
46009 |
Spain |